Brief: Lidds: NanoZolid-TLR9 Agonist Demonstrates Strong And Durable Preclinical Anti-Tumoral Effect

Lidds AB

26/10/2020 07:34

Oct 26 (Reuters) - Lidds AB  LIDDS.ST :
    * REG-LIDDS' NANOZOLID-TLR9 AGONIST DEMONSTRATES STRONG AND
DURABLE PRECLINICAL ANTI-TUMORAL EFFECT
    * WE HAVE IDENTIFIED BOTH INTRATUMORAL- AND PLASMA
BIOMARKERS
NEEDED TO MEASURE ACTIVITY OF NZ-TLR9 IN CLINICAL TRIALS.
    * NZ-TLR9 FORMS AN INTRATUMORAL DEPOT WHICH RELEASES TLR9
AGONIST
FOR LEAST 6 WEEKS AND THUS MINIMIZES NEED FOR REPEATED
INJECTIONS
    * STUDY ALSO IDENTIFIED PLASMA BIOMARKERS WHICH ARE SUITABLE
TO
MEASURE BIOLOGICAL ACTIVITY OF NZ-TLR9 IN COMING CLINICAL TRIAL.
    * PLANNING FOR A PHASE I STUDY TREATING SOLID TUMORS WITH
INTRATUMORAL NZ-TLR9 IS ONGOING AND WE PLAN TO START STUDY
TOWARDS SECOND HALF OF 2021

Source text for Eikon:  ID:nGNE3HT6wY 
Further company coverage:  LIDDS.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))